As part of our commitment to driving improvements and Integration in Health and Social Care, NESCHA Board member Derek Stow felt it only right that he should volunteer for the Novavax Trials that are been carried out at Hartlepool General Hospital and he has now had confirmation of his acceptance to the Trial.
Derek felt that as he is in the over 70’S age group who are most vulnerable to the Virus he recognised that he was also in the group who may benefit most from the development of a successful vaccine and that older volunteers were vital for the research.
North Tees and Hartlepool NHS Foundation Trust has been at the centre of research into the global response to the unprecedented threat of COVID-19.
They were recently commended for their Outstanding Research Contribution from the Clinical Research Network North East and North Cumbria for their role in the RECOVERY trial, a national clinical trial to identify treatments for people hospitalised with COVID-19.
The current Novavax vaccine trial is a partnership led by Durham Tees Valley Research Alliance together North Tess and Hartlepool NHS Trust, South Tees Hospitals NHS Foundation Trust and County Durham and Darlington NHS Foundation Trust and is yet one more example of local our medical expertise being called upon on a global level.
The Novavax trial, which has been rolled out across parts of the UK, has already seen tens of thousands of volunteers take part in the world’s first Phase 3 study to test the effectiveness of the new Novavax Coronavirus vaccine.
The influential Health Foundation press release today
An article which one of our members, Margaret Ogden, co-authored
NESCHA played a key part in the consultation